New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

The Institute for Therapeutic Discovery Licenses Respiratory Health Product to Allergy Research Group

ALBANY, N.Y., Sep 28, 2004 (BUSINESS WIRE) -- The Institute for Therapeutic Discovery has licensed its DNA-based nutritional supplement that promotes respiratory health to Allergy Research Group.

They will market this product as "Mucolyxir" to health professionals and through their label NutriCology, Inc., to retail outlets.

One method by which the body attempts to keep the lungs clear of mucus is to mount an immune response against the agent, or agents, causing the problem. The viscosity of mucus, for example, is commonly attributed to excessive DNA resulting from a build up of lysed white blood cells from the body's failed attempt to eliminate foreign material. With the Institute's formulation, the small amount of DNA used may balance mucus levels via a neutralization or feedback mechanism just as a small amount of ragweed extract is used to down regulate or balance immune response to environmental factors.

Based on pre-clinical investigations, patents, and clinical trials, it is thought that this formulation may increase the strength and frequency of the beat of cilia that line both the respiratory tract and ear canal. Mucoid fluid then becomes easier to eliminate due to the alteration of liquid and solid portions of the mucus in favor of the liquid, resulting in increased expectoration with decreased effort and enhanced clearance of fluid from the ear canal.

Headquartered in Hayward, CA, Allergy Research Group is headed by Stephen Levine, PhD, and specializes in nutritional supplements backed by scientifically-based innovation and purity of ingredients. The Institute for Therapeutic Discovery, led by John McMichael, PhD, is a not-for-profit research organization specializing in discovery and early-stage development of biologic agents for metabolic support. It is headquartered near Albany, NY, with offices in Boxford, MA, and Richmond, VA.

As part of its not-for-profit charter, the Institute carries an obligation to out-license its products. Several candidates are in development.

For more on the Institute:

The Institute for Therapeutic Discovery

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.